JORDAN – Amman Pharmaceutical Industries (Amman Pharma) has entered into an exclusive marketing and commercialization agreement with global pharma major Lupin Limited (Lupin).

In a press release, Dr. Fadi Alatrash, General Manager of Amman Pharma said: “This partnership is aligned with our mission to provide high-quality products and access to advanced biosimilars to patients in the region.”

Amman Pharma is a leading pharmaceutical manufacturer with operations across the Middle East and North Africa (MENA) and other global markets.

As specified in the new agreement, Amman Pharma will be responsible for supplying Ranibizumab, a biosimilar of Lucentis, in the Middle East.

Amman Pharma will work closely with Lupin, a world-leading biopharmaceutical company, to market and commercialize Ranibizumab across the region.

Through the new exclusive marketing and commercialization agreement, Amman Pharma has added the complex ophthalmic biosimilar medicine to its diverse product portfolio.

This partnership expands our biosimilar portfolio and strengthens our position in the niche Ophthalmology market,” stated Dr. Fadi Alatrash.

Under the new agreement, Amman Pharma will supply Ranibizumab in select territories of Jordan, Saudi Arabia, UAE, Iraq, Lebanon, and other countries across the Gulf Cooperation Council (GCC).

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A).

Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), and Macular Edema Following Retinal Vein Occlusion (RVO).

Ranibizumab is also indicated for the treatment of Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularization (mCNV).

Commenting on the latest tie up with Amman Pharma, Dr. Cyrus Karkaria, President of Biotechnology at Lupin, said: “Our successful development of biosimilar Ranibizumab stands as testament to this commitment.”

Dr. Cyrus Karkaria reiterated Lupin’s dedication to empowering patients by offering timely and widespread access to cutting-edge biologic medication at affordable costs.

Under the exclusive marketing pact, both Amman Pharma and Lupin are united in their mission to provide innovative, high-quality healthcare solutions to patients in the MENA region.

Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

In his address, Nilesh Gupta, Managing Director of Lupin, outlined: “We aim to be at the forefront of transforming patient’s lives and building a healthier, brighter future for all. We are excited about the partnership with Amman Pharma to bring Ranibizumab to the MENA region.”

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.